xRead Articles - October 2022

Laryngeal dysfunction score 24-hr cough frequency (coughs/hr) HRCQ

12 weeks LCQ Cough frequency (cough/hr) Cough symptom score Urge-to-cough score Single dose Capsaicin cough challenge

Capsaicin cough challenge Sputum neutrophil count Rate of cough control LCQ

Secondary outcome measure(s)

Sputum examination

Cough severity VAS

Urge-to-cough VAS CQLQ

Serum examination CQLQ

Exhaled NO and CO PFTs

Cough symptom diary

Citric acid cough challenge LCQ

Cough VAS

2 weeks Cough symptom diary Cough severity VAS 12 weeks 24-hr cough frequency (coughs/hr) 8 weeks Cough symptom score

2 weeks Cough discomfort VAS

4 weeks Capsaicin cough challenge

2 weeks Cough severity VAS Sputum examination 10 days Reduction in cough frequency and severity 4 weeks LCQ Number of patients with sedation

Primary outcome measure

Treatment

duration

oral prednisone 25 mg daily × 1

week + inhaled budesonide 200 μ g/inhalation BID

+ domperidone 10 mg TID (120)

Bronchodilator and antihistamine

Methoxyphenamine 2 capsules TID + cetirizine 10 mg daily Corticosteroid

intervention (n patients) Placebo

inhaler, 1 inhalation BID (24) Placebo

PPI and antimotility agent omeprazole 20 mg BID Placebo

oral tablets (30)

oral tablet

Comparator

inhaler, 1 inhalation BID

Placebo

oral tablet daily

inhaler, 2 inhalation TID (20) Placebo

oral tablet daily (15)

Codeine/guaifenesin Placebo

100 mg/5 mL, 10 mL q6hr (13) oral tablet BID Placebo

beclomethasone 500 μ g/ inhalation TID (44)

PPI and antimotility agent : omeprazole 20 mg BID

Jeyakumar et al (2006) Cleveland, OH, USA Parallel RCT 28; 28 (13/15) E: 54.6 C: 49.7 Tricyclic antidepressant : amitriptyline 10 mg qHS (15) Morice et al (2007) East Yorkshire, England, UK 27; 27 (9/18) 55 Opioid analgesic : morphine 5 mg BID

Hamilton, Ontario, CAN Parallel RCT 48; 44 (16/28) E: 43 C: 47 Inhaled corticosteroid : budesonide 400 μ g/

Glasgow, Scotland, UK Crossover RCT 93; 88 (32/57) 59 Inhaled corticosteroid : fl uticasone 500 μ g/ inhalation BID

Ribeiro et al (2007) Sao Paulo, Brazil Parallel RCT 64; 64 (22/42) E: 46 C: 50 Inhaled corticosteroid :

Yousaf et al (2009) Leicester, England, UK Parallel RCT 30; 28 (6/24) E: 63 C: 61 Macrolide antibiotic :

200 mg TID + cetirizine 10 mg daily Corticosteroid : oral prednisone 25 mg daily × 1 week

Khalid et al (2014) Manchester, England, UK Crossover RCT 21; 19 (6/15) 53 TRPV-1 inhibitor : SB-705498 Placebo

Ryan et al (2012) Newcastle, NSW, Australia Parallel RCT 62; 52 (22/40) E: 62.7 C: 60.9 Neuromodulator : Gabapentin

Bronchodilator and antihistamine : diprophylline

TABLE I.

Ternesten-Hasseus et al (2014) Gothenburg, Sweden Crossover RCT 24; 22 (2/22) 52 Capsaicin capsule 0.4 mg BID × 2 weeks, then 0.8 mg BID × 2 weeks

+ inhaled budesonide 200 μ g/inhalation BID

inhalation BID (24)

titrated up to 1800 mg daily, then tapered off (32)

erythromycin 250 mg daily (15)

+ domperidone 10 mg TID (120)

Experimental intervention (n patients)

Characteristics of Included Studies, Strati fi ed by Intervention Type: Medical Therapy, Speech Therapy, Procedural Therapy. Study design # Patients enrolled; completed therapy (males/females) Average age in years Crossover RCT post hoc analysis of AEs

Qiu et al (2010) Shanghai, China Parallel RCT 240; 214 (93/147) E: 45 C: 45

trial number (year) Location

Pizzichini et al (1999)

Chaudhuri et al (2004)

Author or clinical

Medical therapy

Dickinson et al (2014)

Laryngoscope 132: January 2022

Wamkpah et al.: Multimodal Treatments for Neurogenic Cough

110